Biotech

05/25/25

No More Freeriding on the Great American Drug Deal

Biotech

Policy

05/15/25

NPLB’s GCEA Calculator

Biotech

Finance

Policy

Planetary

05/14/25

Writing the future of genetic medicines, with Stylus

Biotech

Finance

Science

04/03/25

Showing the math: How IRA destroys NPV

Biotech

Finance

Policy

02/15/25

A Vaccine for your Mind

Biotech

Culture

Science

02/13/25

2025 Pharma Superbowl Ads: Moving … but not moving the needle where it matters most

Biotech

Culture

01/31/25

How to navigate and de-risk your next career move in biotech (2025)

Biotech

Culture

01/30/25

Introducing Biotech Unveiled

Biotech

Culture

01/11/25

Semper Maior: Pumping up the candor

Biotech

Culture

Finance

12/20/24

What you were reading — Rapport’s top stories of 2024

Biotech

Culture

Finance

Policy

Science

Planetary

12/18/24

ESPN always shows the struggle; this time, it’s mine

Biotech

Culture

Science

12/06/24

“Keep it under 20”

Biotech

Culture

11/27/24

A lot for a little: The best 8% slice of our healthcare dollar

Biotech

Policy

11/20/24

Utilizing investors on and off your Board

Biotech

Culture

11/15/24

The way forward for therapeutics value assessment

Biotech

Policy

11/13/24

Managing pain without opioids is on the horizon – if we decide it’s worth it

Biotech

Policy

Science

10/28/24

Raven-built Aliada shuttles its potential best-in-class Alzheimer’s treatment to AbbVie

Biotech

Finance

Science

10/18/24

How do you resolve conflict among board members and executives?

Biotech

Culture

10/14/24

The political rot eroding our national health security

Biotech

Policy

09/30/24

What makes a good board chair?

Biotech

Culture